Tags

Type your tag names separated by a space and hit enter

Use of asenapine as add-on therapy in the treatment of bipolar disorder: a comprehensive review and case series.
Expert Opin Drug Saf. 2014 Sep; 13(9):1199-208.EO

Abstract

INTRODUCTION

Several randomized controlled trials (RCTs), conducted in schizophrenic and bipolar patients, have documented the efficacy and tolerability of asenapine as monotherapy both for short- and long-term treatment. However, evidence on its augmentative use is more limited and related to the manic/mixed phase of bipolar disorder (BD).

AREAS COVERED

The present article reviews augmentative asenapine efficacy and safety/tolerability in the treatment of BD. It also includes some original cases of bipolar patients treated with add-on asenapine in the short- and long-term.

EXPERT OPINION

To date, only a single RCT with manic/mixed patients with partial response to mood-stabilizer monotherapy supports the efficacy and safety/tolerability of augmentative asenapine to lithium/valproate, both in acute and long-term treatment. Additionally, two case reports confirm the overall effectiveness of augmentative asenapine to clozapine and valproate. Our case series, consisting of 4 bipolar patients treated with adjunctive asenapine to mood stabilizers and atypical antipsychotics - with treatment duration ranging from 1 to 14 months - provided clinical results that are consistent with literature data. Taken as a whole, available evidence seems to support the efficacy and safety of adjunctive asenapine in bipolar patients, though additional studies with active comparators are requested to confirm the current body of evidence.

Authors+Show Affiliations

Università degli Studi di Milano, Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda, Dipartimento di Fisiopatologia medico-chirurgica e dei trapianti, Dipartimento di Salute Mentale , Via Francesco Sforza 35, Milano , Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Review

Language

eng

PubMed ID

25084462

Citation

Dell'Osso, Bernardo, et al. "Use of Asenapine as Add-on Therapy in the Treatment of Bipolar Disorder: a Comprehensive Review and Case Series." Expert Opinion On Drug Safety, vol. 13, no. 9, 2014, pp. 1199-208.
Dell'Osso B, Cremaschi L, Palazzo MC, et al. Use of asenapine as add-on therapy in the treatment of bipolar disorder: a comprehensive review and case series. Expert Opin Drug Saf. 2014;13(9):1199-208.
Dell'Osso, B., Cremaschi, L., Palazzo, M. C., Spagnolin, G., Cattaneo, A., Grancini, B., Maggi, M., & Altamura, A. C. (2014). Use of asenapine as add-on therapy in the treatment of bipolar disorder: a comprehensive review and case series. Expert Opinion On Drug Safety, 13(9), 1199-208. https://doi.org/10.1517/14740338.2014.938047
Dell'Osso B, et al. Use of Asenapine as Add-on Therapy in the Treatment of Bipolar Disorder: a Comprehensive Review and Case Series. Expert Opin Drug Saf. 2014;13(9):1199-208. PubMed PMID: 25084462.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of asenapine as add-on therapy in the treatment of bipolar disorder: a comprehensive review and case series. AU - Dell'Osso,Bernardo, AU - Cremaschi,Laura, AU - Palazzo,Maria Carlotta, AU - Spagnolin,Gregorio, AU - Cattaneo,Alma, AU - Grancini,Benedetta, AU - Maggi,Matteo, AU - Altamura,Alfredo Carlo, Y1 - 2014/08/01/ PY - 2014/8/2/entrez PY - 2014/8/2/pubmed PY - 2015/3/17/medline KW - add-on therapy KW - asenapine KW - bipolar disorder KW - efficacy KW - tolerability SP - 1199 EP - 208 JF - Expert opinion on drug safety JO - Expert Opin Drug Saf VL - 13 IS - 9 N2 - INTRODUCTION: Several randomized controlled trials (RCTs), conducted in schizophrenic and bipolar patients, have documented the efficacy and tolerability of asenapine as monotherapy both for short- and long-term treatment. However, evidence on its augmentative use is more limited and related to the manic/mixed phase of bipolar disorder (BD). AREAS COVERED: The present article reviews augmentative asenapine efficacy and safety/tolerability in the treatment of BD. It also includes some original cases of bipolar patients treated with add-on asenapine in the short- and long-term. EXPERT OPINION: To date, only a single RCT with manic/mixed patients with partial response to mood-stabilizer monotherapy supports the efficacy and safety/tolerability of augmentative asenapine to lithium/valproate, both in acute and long-term treatment. Additionally, two case reports confirm the overall effectiveness of augmentative asenapine to clozapine and valproate. Our case series, consisting of 4 bipolar patients treated with adjunctive asenapine to mood stabilizers and atypical antipsychotics - with treatment duration ranging from 1 to 14 months - provided clinical results that are consistent with literature data. Taken as a whole, available evidence seems to support the efficacy and safety of adjunctive asenapine in bipolar patients, though additional studies with active comparators are requested to confirm the current body of evidence. SN - 1744-764X UR - https://www.unboundmedicine.com/medline/citation/25084462/Use_of_asenapine_as_add_on_therapy_in_the_treatment_of_bipolar_disorder:_a_comprehensive_review_and_case_series_ L2 - http://www.tandfonline.com/doi/full/10.1517/14740338.2014.938047 DB - PRIME DP - Unbound Medicine ER -